September 11, 2020

Work with Dr. Priyamvada Acharya on Special Issue "Structural Biology of HIV-1 Entry"

via MDPI 

Work with one of the best! Does your lab study the "Structural Biology of HIV-1 Entry"? Submit your work to collaborate with DHVI's Director of Structural Biology, Dr. Priyamvada Acharya and her extraordinary team.

Special Issue "Structural Biology of HIV-1 Entry"

Dr. Priyamvada Acharya is leading a Special Issue "Structural Biology of HIV-1 Entry" in Viruses. We encourage topics that cover current knowledge in the field on the structural biology of #HIV-1 entry.

Dr. Priyamvada Acharya Website
Guest Editor

Duke University School of Medicine, Durham, USA
Interests: structural biology and mechanism of HIV-1 entry; HIV-1 vaccine design; HIV-1 entry inhibitors; SARS-CoV-2 spike structural biology and vaccine design

Special Issue Information

HIV-1 entry is mediated by its trimeric Envelope (Env) surface glycoprotein.  Binding of the gp120 subunit to host cell surface CD4 receptor triggers Env conformational changes that expose the binding site for a co-receptor, typically CCR5 or CXCR4. Additional conformational changes that follow co-receptor binding lead to membrane fusion. Env conformational changes on the HIV-1 entry pathway are mediated by an allosteric network of protein contacts that facilitate receptor-mediated structural changes at sites distal from the receptor binding site. Env is the sole target for neutralizing antibodies on the HIV-1 surface. Regions that are critical for entry, such as receptor binding sites and the fusion peptide, are vulnerable and are thus protected by multiple immune evasion mechanisms. The HIV-1 entry pathway can also be effectively targeted by entry inhibitors, exemplified by enfuvirtide and maraviroc, both licensed antiretroviral drugs that target different steps on the entry pathway.  Structural biology of HIV-1 entry has been a subject of intense investigations for many years, and is closely tied to efforts to develop an effective HIV-1 vaccine. In this Special Issue, we will gather and connect existing knowledge in the field on the structural biology of HIV-1 entry and reflect on how this informs HIV-1 vaccine and therapeutics development.

Dr. Priyamvada Acharya
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • HIV-1 entry
  • HIV-1 envelope
  • gp120
  • gp41
  • CD4
  • CCR5
  • CXCR5
  • Conformational change
  • Allostery
  • HIV-1 vaccine
  • Entry inhibitors

Published Papers

This special issue is now open for submission.